PE20121359A1 - Composicion farmaceutica que comprende oligopeptidos - Google Patents

Composicion farmaceutica que comprende oligopeptidos

Info

Publication number
PE20121359A1
PE20121359A1 PE2012000796A PE2012000796A PE20121359A1 PE 20121359 A1 PE20121359 A1 PE 20121359A1 PE 2012000796 A PE2012000796 A PE 2012000796A PE 2012000796 A PE2012000796 A PE 2012000796A PE 20121359 A1 PE20121359 A1 PE 20121359A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
gly
asp
arg
composition including
Prior art date
Application number
PE2012000796A
Other languages
English (en)
Inventor
Marcus Eber
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44145957&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121359(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PE20121359A1 publication Critical patent/PE20121359A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Abstract

REFERIDA A UNA COMPOSICION QUE COMPRENDE: a) 12% A 90% DE UN OLIGOPEPTIDO TAL COMO CICLO-(Arg-Gly-Asp-DPhe-NMeVal), CICLO-(Arg-Gly-Asp-DPhe-vAL), Arg-Gly-Asp, ENTRE OTROS, b) 0,01% A 60% DE UNO O VARIOS COMPUESTOS LIPOFILICOS Y/O ANFIFILICOS, Y OPCIONALMENTE, c) 0% A 89% DE AGUA, DONDE LOS COMPUESTOS LIPOFILICOS Y/O ANFIFILICOS COMPRENDEN UN RESTO GLICEROL, UNO O VARIOS RESTOS DE ACIDOS GRASOS Y/O UNO O VARIOS RESTOS DE ALCOHOLES GRASOS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA
PE2012000796A 2009-12-10 2010-12-06 Composicion farmaceutica que comprende oligopeptidos PE20121359A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28531309P 2009-12-10 2009-12-10
US41662810P 2010-11-23 2010-11-23

Publications (1)

Publication Number Publication Date
PE20121359A1 true PE20121359A1 (es) 2012-10-15

Family

ID=44145957

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000796A PE20121359A1 (es) 2009-12-10 2010-12-06 Composicion farmaceutica que comprende oligopeptidos

Country Status (19)

Country Link
US (1) US9433577B2 (es)
EP (1) EP2509583B1 (es)
JP (1) JP5946770B2 (es)
KR (1) KR20120104316A (es)
CN (1) CN102652015B (es)
AU (1) AU2010330364B2 (es)
BR (1) BR112012012862A2 (es)
CA (1) CA2783732A1 (es)
CL (1) CL2012001310A1 (es)
EA (1) EA022700B1 (es)
EC (1) ECSP12012031A (es)
ES (1) ES2742263T3 (es)
IL (1) IL220097A (es)
MX (1) MX2012006450A (es)
NZ (1) NZ601109A (es)
PE (1) PE20121359A1 (es)
SG (1) SG181487A1 (es)
WO (1) WO2011069629A2 (es)
ZA (1) ZA201205103B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA022831B1 (ru) * 2009-05-20 2016-03-31 Мерк Патент Гмбх Твердые формы {[(2s,5r,8s,11s)-5-бензил-11-(3-гуанидинопропил)-8-изопропил-7-метил-3,6,9,12,15-пентаоксо-1,4,7,10,13-пентаазациклопентадец-2-ил]уксусной кислоты} и способы их получения
ES2788863T3 (es) 2010-05-14 2020-10-23 Massachusetts Gen Hospital Composiciones de neoantígenos específicos de un tumor para uso en el tratamiento de tumores
JP2014516996A (ja) * 2011-06-09 2014-07-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング キャリア中のシレンギチドの懸濁液による癌および転移の処置
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
CN108025048B (zh) 2015-05-20 2022-10-25 博德研究所 共有的新抗原
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
AU2018321157B2 (en) 2017-08-24 2024-03-28 Novo Nordisk A/S GLP-1 compositions and uses thereof
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
IL294520A (en) 2020-02-18 2022-09-01 Novo Nordisk As Pharmaceutical formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE921212A1 (en) * 1991-04-19 1992-10-21 Affinity Biotech Inc Convertible microemulsion formulations
CA2114323A1 (en) * 1991-07-26 1993-02-18 Panayiotis Pericleous Constantinides W/o microemulsions
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
NZ333844A (en) * 1996-08-22 2000-10-27 Res Triangle Pharm Ltd Compositions comprising mircoparticles of water-insoluble substances and method for preparing same
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
UA71608C2 (en) 1999-03-11 2004-12-15 Merck Patent Gmbh A method for producing the cyclic pentapeptide
EP2116228A1 (en) * 2001-10-19 2009-11-11 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
US6656460B2 (en) * 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
DE10228049A1 (de) * 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
MXPA05012467A (es) 2003-05-19 2006-02-22 Baxter Int Particulas solidas que comprenden un anticonvulsivo o un inmunosupresor revestido con uno o mas modificadores de superficie.
US7749485B2 (en) * 2004-06-03 2010-07-06 Bracco Research S.A. Liposomal assembly for therapeutic and/or diagnostic use
JP2010539044A (ja) 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト メラノトロピンを増強する因子の治療剤としての使用
WO2009124754A1 (en) * 2008-04-08 2009-10-15 Merck Patent Gmbh Compositions containing cyclic peptides and methods of use
EA022831B1 (ru) * 2009-05-20 2016-03-31 Мерк Патент Гмбх Твердые формы {[(2s,5r,8s,11s)-5-бензил-11-(3-гуанидинопропил)-8-изопропил-7-метил-3,6,9,12,15-пентаоксо-1,4,7,10,13-пентаазациклопентадец-2-ил]уксусной кислоты} и способы их получения

Also Published As

Publication number Publication date
JP2013513556A (ja) 2013-04-22
KR20120104316A (ko) 2012-09-20
EA201200850A1 (ru) 2013-01-30
NZ601109A (en) 2014-06-27
CN102652015A (zh) 2012-08-29
EP2509583A2 (en) 2012-10-17
WO2011069629A2 (en) 2011-06-16
AU2010330364B2 (en) 2016-05-19
SG181487A1 (en) 2012-07-30
CN102652015B (zh) 2016-08-03
CA2783732A1 (en) 2011-06-16
US9433577B2 (en) 2016-09-06
MX2012006450A (es) 2012-06-28
ES2742263T3 (es) 2020-02-13
ECSP12012031A (es) 2012-08-31
US20120288539A1 (en) 2012-11-15
WO2011069629A3 (en) 2012-03-15
EA022700B1 (ru) 2016-02-29
EP2509583B1 (en) 2019-05-15
JP5946770B2 (ja) 2016-07-06
CL2012001310A1 (es) 2012-10-12
AU2010330364A1 (en) 2012-07-26
ZA201205103B (en) 2013-03-27
BR112012012862A2 (pt) 2016-08-16
IL220097A (en) 2017-03-30

Similar Documents

Publication Publication Date Title
PE20121359A1 (es) Composicion farmaceutica que comprende oligopeptidos
CY1119784T1 (el) Ακετυλιωμενες σαλικυλικες ενωσεις λιπαρου οξεος και οι χρησεις αυτων
CY1120888T1 (el) Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες
ES2580635T3 (es) Composición cosmética que comprende un agente estructurante, un agente absorbente y un agente tensioactivo para la aplicación a las materias queratínicas
UY34112A (es) Composiciones farmacéuticas que contienen un agente neuroléptico y un inhibidor sglt2 y usos de los mismos
ITVA20110027A1 (it) Composizioni per la cura della persona
CO7160059A2 (es) Formulación líquida
ECSP10010433A (es) Composición que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes ácidas
AR082051A1 (es) Composicion antimicrobial para enjuague bucal reducida en alcohol
DOP2012000261A (es) Formulaciones de insulina de accion prolongada
CO6491099A2 (es) Sistemas para el cuidado bucal
AR089007A1 (es) Composicion aditiva para fluidos de tratamiento de pozos
CO6210786A2 (es) Implemento de cuidado oral que alberga un agente de cuidado oral
CL2012002742A1 (es) Composicion acuosa estable de silicato de metal alcalino que comprende un osmolito; uso de dicha composicion para proteger cultivos o para preparar composicion farmaceutica o cosmetica o un suplemento de alimentos o alimenticio.
CL2008003907A1 (es) Composiciones de limpieza que comprende alquilpoliglucosido, alcohol de 2 a 4 atomos de carbono, glicerol, y componentes opcionales, tales como acidos organicos solubles en agua, fragancias, reforzadores;
CO6531452A2 (es) Piperidinas sustituidas que aumentan la actividad de p53 y sus usos
PE20141358A1 (es) Polimorfos de inhibidores de cinasas
ECSP088214A (es) Formulaciones de acetato de bazedoxifeno que tienen una conversión polimórfica reducida
ES2484721T3 (es) Mezcla fluidizante para composición hidráulica
UY32704A (es) Compuestos de 2,3-dihidro-1h-indeno
CL2013002234A1 (es) Uso de una composicion farmaceutica que comprende al menos una prostaciclina o un analogo de la misma seleccionado entre treprostinil, ilorpost, cicaprost o beraprost, y al menos un inhibidor de fosfodiesterasa 4 (pde4), porque sirve en la prevencion o tratamiento de la fibrosis quistica.
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
AR078142A1 (es) Compuestos inhibidores heteroarilicos biciclicos de pde4, las composiciones farmaceuticas que los contienen y el uso de los mismos para la preparacion de medicamentos.
AR094015A1 (es) Metodos para blanquear los dientes
NO20071485L (no) Kjemiske substanser.

Legal Events

Date Code Title Description
FD Application declared void or lapsed